Cinobufacini Tablets Combined With Chemotherapeutic Protocol in Treatment of Diffuse Large B Cell Lymphoma

For control and trial groups A: Inclusion Criteria: * Patients aged 18-70 years old; * Patients with eastern Collaborative Oncology Group (ECOG) performance status (PS) score: 0～3 points; * International prognostic index (IPI): ≤3 points; * Patients who were diagnosed as diffuse large B cell lymphoma (DLBCL) with initial treatment by histopathology; * Patients with more than 1 measurable nidus (common CT or MRI scanning diameter ≥ 20 mm, and spiral CT scanning diameter ≥ 10 mm); * Patients without dysfunction of important organs, and had normal blood routine, hepatorenal function and cardiac function. White blood cell count (WBC) ≥4.0×109/L, neutrophil count ≥1.5×109/L; platelet (PLT) count ≥100×109/L; hemoglobin (HGB) ≥95g/L; serum bilirubin (Bil) ≤1.5 folds of the upper limit of normal value, alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤2 folds of the upper limit of normal value, and serum creatinine (Scr) ≤1.5mg/dl; * Patients with expected survival time\>3 months; * Patients who were well informed of this study and signed the informed consent forms. * Patients who received administration of Rituximab. Exclusion Criteria: * Patients who did not conform to above criteria; * Patients who were receiving other anti-cancer therapies; * Patients with DLBCL affected by primary breast gland, lung, testis, bone, peri-orbit, peri-spine, central nerve system and bone marrow; * Patients with double expression, double strike, trinary expression and trinary strike and CD5+; * Patients complicated with other non-DLBCL primary malignant tumors; * Patients who had poor compliance with their families; * Patients with one of the following conditions: uncontrolled metastatic nidi of central nerve system, dysfunction of important organs and severe cardiac diseases like congestive heart failure, uncontrollable arrhythmia, angina pectoris that needed long-term drug administration, valvular heart diseases, myocardial infarction and refractory hypertension, pregnancy or lactation, chronic infectious wounds, and history of uncontrollable psychological diseases. * Patients had previous history of treatment with Cinobufacini Tablets. For control and trial groups B Inclusion Criteria: * Patients aged 18-70 years old; * Patients with eastern Collaborative Oncology Group (ECOG) performance status (PS) score: 0～3 points; * International prognostic index (IPI): ≤3 points; * Patients who were diagnosed as diffuse large B cell lymphoma (DLBCL) with initial treatment by histopathology; * Patients with more than 1 measurable nidus (common CT or MRI scanning diameter ≥ 20 mm, and spiral CT scanning diameter ≥ 10 mm); * Patients without dysfunction of important organs, and had normal blood routine, hepatorenal function and cardiac function. White blood cell count (WBC) ≥4.0×109/L, neutrophil count ≥1.5×109/L; platelet (PLT) count ≥100×109/L; hemoglobin (HGB) ≥95g/L; serum bilirubin (Bil) ≤1.5 folds of the upper limit of normal value, alanine transaminase (ALT) and aspartate aminotransferase (AST) ≤2 folds of the upper limit of normal value, and serum creatinine (Scr) ≤1.5mg/dl; * Patients with expected survival time\>3 months; * Patients who were well informed of this study and signed the informed consent forms. * Patients who did not receive administration of Rituximab. Exclusion Criteria: * Patients who did not conform to above criteria; * Patients who were receiving other anti-cancer therapies; * Patients with DLBCL affected by primary breast gland, lung, testis, bone, peri-orbit, peri-spine, central nerve system and bone marrow; * Patients with double expression, double strike, trinary expression and trinary strike and CD5+; * Patients complicated with other non-DLBCL primary malignant tumors; * Patients who had poor compliance with their families; * Patients with one of the following conditions: uncontrolled metastatic nidi of central nerve system, dysfunction of important organs and severe cardiac diseases like congestive heart failure, uncontrollable arrhythmia, angina pectoris that needed long-term drug administration, valvular heart diseases, myocardial infarction and refractory hypertension, pregnancy or lactation, chronic infectious wounds, and history of uncontrollable psychological diseases. * Patients had previous history of treatment with Cinobufacini Tablets.